Education
About Us
Working with TipRanks
Follow Us
ClearPoint Neuro (CLPT)
NASDAQ:CLPT
CLPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.11 - $19.22
Previous CloseN/A
Volume88.39K
Average Volume (3M)241.38K
Market Cap
$358.14M
Enterprise Value$408.22M
Total Cash (Recent Filing)$1.68M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 13, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding27,979,560
10 Day Avg. Volume238,088
30 Day Avg. Volume241,382
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.78
Price to Cash Flow (P/CF)-71.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.35
Enterprise Value/Ebitda-22.36
Forecast
1Y Price Target
$22.50Price Target Upside69.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
ClearPoint Neuro News
PremiumCompany Announcements
ClearPoint Neuro’s Earnings Call Highlights Robust Growth
PremiumCompany Announcements
ClearPoint Neuro Achieves Record Growth in 2024
PremiumCompany Announcements
ClearPoint Neuro Reports Record 2024 Revenue Growth
---
Bulls Say, Bears Say
Bulls Say
EarningsClearPoint's Q3 revenue of $8.1M exceeded expectations, driven by broad-based business strength in both the functional neuro and biologic and drug delivery businesses.
Financial PerformanceThe balance sheet is solid with over $20M of cash and no debt.
Market PositionClearPoint has established itself as the go-to provider for neurosurgery guidance – regardless of the operating location.
Bears Say
Regulatory ChallengesClearPoint is expected to apply the process learnings from PTC to its other indications to assist with efficient time through the device side of the FDA review process.
---
Ownership Overview
10.44% Insiders
6.26% Mutual Funds
0.95% Other Institutional Investors
77.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLPT FAQ
What was ClearPoint Neuro’s price range in the past 12 months?
ClearPoint Neuro lowest stock price was $5.11 and its highest was $19.22 in the past 12 months.
What is ClearPoint Neuro’s market cap?
ClearPoint Neuro’s market cap is $358.14M.
When is ClearPoint Neuro’s upcoming earnings report date?
ClearPoint Neuro’s upcoming earnings report date is May 13, 2025 which is in 19 days.
How were ClearPoint Neuro’s earnings last quarter?
ClearPoint Neuro released its earnings results on Feb 26, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.036.
Is ClearPoint Neuro overvalued?
According to Wall Street analysts ClearPoint Neuro’s price is currently Undervalued.
Does ClearPoint Neuro pay dividends?
ClearPoint Neuro does not currently pay dividends.
What is ClearPoint Neuro’s EPS estimate?
ClearPoint Neuro’s EPS estimate is -0.16.
How many shares outstanding does ClearPoint Neuro have?
ClearPoint Neuro has 27,979,560 shares outstanding.
What happened to ClearPoint Neuro’s price movement after its last earnings report?
ClearPoint Neuro reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went down -17.538%.
Which hedge fund is a major shareholder of ClearPoint Neuro?
Currently, no hedge funds are holding shares in CLPT
---
ClearPoint Neuro Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (69.81% Upside)
$22.50 (69.81% Upside)
Blogger Sentiment
Bullish
CLPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 29.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
132.30%
12-Months-Change
Fundamentals
Return on Equity
-81.24%
Trailing 12-Months
Asset Growth
-8.14%
Trailing 12-Months
Company Description
ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
---
CLPT Company Deck
---
CLPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
ClearPoint Neuro demonstrated strong financial performance with significant revenue growth across various segments and improved gross margins. The company launched several new products and achieved a debt-free status, indicating positive strategic progress. However, there were challenges with a decrease in cash position and increased operating expenses, which slightly dampen the overall positive outlook.Read More>---
CLPT Stock 12 Month Forecast
Average Price Target
$22.50
▲(69.81% Upside)
Technical Analysis
Pacific Biosciences
―
Tactile Systems Technology
―
Varex Imaging
―
Nano-X Imaging
―
NeuroPace
―
Best Analysts Covering CLPT
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+37.65%
reiterated a buy rating 16 hours ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +37.65% per trade.
---